MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

PHASE2CompletedINTERVENTIONAL

Enrollment

407

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

July 31, 2005

Study Completion Date

January 31, 2007

Conditions

Hypercholesterolemia

Interventions

DRUG

Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks

DRUG

MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks

DRUG

Comparator : niacin / Duraton of Treatment: 4 Weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00533312 - MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED) | Biotech Hunter | Biotech Hunter